Results 181 to 190 of about 64,598 (305)
Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer. [PDF]
Wangsatidtongbai P +2 more
europepmc +1 more source
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
Erratum to "Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease" by Boo EK, et al. (Yonsei Med J 2026;67(8):603-615). [PDF]
europepmc +1 more source
Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies. [PDF]
Wang X, Fu S, Zhu X, Zhao Y.
europepmc +1 more source
Rheumatologic Manifestations of Patients With Type B Insulin Resistance
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya +4 more
wiley +1 more source
From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis. [PDF]
Lv F +5 more
europepmc +1 more source
This prospective study observed that preoperative chemoradiotherapy for rectal cancer was associated with reductions in body fat and grip strength, which appeared to be more pronounced in female patients. These findings suggest that sex‐sensitive nutritional and exercise support may be beneficial to help maintain muscle mass and physical function ...
Shinya Abe +9 more
wiley +1 more source
Extranodal natural killer/T-cell lymphoma: From fatal to curable. [PDF]
Xiong J +12 more
europepmc +1 more source
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen +26 more
wiley +1 more source

